Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX Genomic Prostate Score® Test.

Products are for professional/laboratory use only.

On the 3^rd of December, Genomic Health, Inc and Biocartis Group NV announced that they have expanded their exclusive collaboration into the field of urology with the development of an in vitro diagnostic (IVD) version* of the Oncotype DX Genomic Prostate Score® (GPS™) Test on Biocartis’ Idylla™ platform and potentially additional cancer tests that can be performed locally by laboratory partners and in hospitals around the world.

*test may not be approved for IVD use in your country, please check with Abacus dx

Go Back